Both in R&D — Physical & Biological Sciences
IB Acquisition vs MaxCyte
Over the past year IBAC returned +3.7% and MXCT returned −1.4%; their daily moves had a correlation of 0.03.
IBAC +3.7% MXCT −1.4%Growth of $1, one year, split-adjusted
| Metric | IBAC | MXCT |
|---|---|---|
| Price | $10.81 | $1.34 |
| Market cap | $54.1M | $138.3M |
| Today | −0.46% | −3.60% |
| 1 month | −0.6% | +28.8% |
| 6 months | −0.2% | +53.8% |
| Year to date | +3.0% | −13.5% |
| 1 year | — | −16.8% |
| Revenue growth (YoY) | — | −14.5% |
| Gross margin | — | 77.0% |
| Net margin | — | −122.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 4.5× |
| Net cash | — | $105.7M |
| Dividend yield | — | — |
| Volatility (60d) | 20.1% | 82.5% |
| Short % of float | 0.3% | 2.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).